1. Atrial pacing in Fontan patients: The effect of transvenous lead on clot burden
- Author
-
Michelle Gurvitz, Edward T. O’Leary, Douglas Y. Mah, Rahul H. Rathod, Francis Fynn-Thompson, Tony Pastor, Elizabeth S. DeWitt, Iqbal El Assaad, Fred M. Wu, and Kimberlee Gauvreau
- Subjects
Adult ,Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Adolescent ,030204 cardiovascular system & hematology ,Fontan Procedure ,Rate ratio ,Intracardiac injection ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,cardiovascular diseases ,030212 general & internal medicine ,Retrospective Studies ,Sick Sinus Syndrome ,Aspirin ,business.industry ,Cardiac Pacing, Artificial ,Warfarin ,Anticoagulants ,Thrombosis ,Retrospective cohort study ,medicine.anatomical_structure ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Artery - Abstract
Background Transvenous permanent pacemaker (PPM) implantation is an available option for Fontan patients with sinus node dysfunction. However, the thrombogenic potential of leads within the Fontan baffle is unknown. Objective The purpose of this study was to compare the clot burden in Fontan patients with a transvenous atrial PPM to those without a PPM and those with an epicardial PPM. Methods This was a retrospective cohort study of all transvenous PPM implantations in Fontan patients followed at our institution (2000–2018). We performed frequency matching on Fontan type and age group. Primary outcome was identification of intracardiac clot, pulmonary embolus, or embolic stroke. Results Of 1920 Fontan patients, 58 patients (median age 23 years; interquartile range [25th–75th percentiles] 14–33) at the time of transvenous PPM implantation and 174 matched subjects formed our cohort. The type of Fontan performed in case subjects was right atrium–pulmonary artery or right atrium–right ventricle conduit (54%), lateral tunnel (43%), and extracardiac (3%). The cumulative incidence of clot was highest in patients with transvenous PPM, followed by patients with epicardial PPM and no PPM (1.2 vs 0.87 vs 0.67 per 100 person-years of follow-up, respectively). In multivariable analysis, anticoagulation and/or antiplatelet therapy were protective against clot and resulted in reduction of clot risk by 3-fold (incidence rate ratio 0.33; 95% confidence interval 0.21–0.53; P Conclusion In a large cohort of Fontan patients matched for age and Fontan type, patients with transvenous PPM had a higher but not statistically significant incidence of clot compared to those with no PPM and epicardial PPM. Patients treated with warfarin/aspirin had lower clot risk.
- Published
- 2021
- Full Text
- View/download PDF